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Background: A small percentage of human immunodeficiency virus (HIV)-infected people and simian
immunodeficiency virus (SIV)-infected macaques control virus replication without antiretroviral treatment. The major
determinant of this control is host expression of certain major histocompatibility complex alleles. However, this
association is incompletely penetrant, suggesting that additional loci modify the major histocompatibility complex’s
protective effect. Here, to identify candidate control-modifying loci, we sequence the genomes of 12 SIV-infected
Mauritian cynomolgus macaques that experienced divergent viral load set points despite sharing the protective M1
major histocompatibility complex haplotype.
Results: Our genome-wide analysis of haplotype-level variation identifies seven candidate control-modifying loci on
chromosomes 2, 3, 7, 8, 9, 10, and 14. The highest variant density marks the candidate on chromosome 7, which is
the only control-modifying locus to comprise genes with known immunological function. Upon closer inspection,
we found an allele for one of these genes, granzyme B, to be enriched in M1(+) controllers. Given its established
role as a cytotoxic effector molecule that participates in CD8-mediated killing of virus-infected cells, we test the
role of variation within gzmb in modifying SIV control by prospectively challenging M1(+) granzyme B-defined
macaques.
Conclusions: Our study establishes a framework for using whole genome sequencing to identify haplotypes
that may contribute to complex clinical phenotypes. Further investigation into the immunogenetics underlying
spontaneous HIV control may contribute to the rational design of a vaccine that prevents acquired immune
deficiency syndrome.Background
The majority of HIV-infected individuals experience
progressive infection, characterized by ongoing virus
replication, CD4(+) cell depletion, and eventually ac-
quired immune deficiency syndrome (AIDS). However,
a rare group of infected individuals spontaneously sup-
press virus replication to low or undetectable levels* Correspondence: doconnor@primate.wisc.edu
1Department of Pathology, University of Wisconsin-Madison, Madison, WI
53705, USA
7Wisconsin National Primate Research Center, Madison, WI 53715, USA
Full list of author information is available at the end of the article
© 2014 Ericsen et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.during chronic infection [1,2]. Although the basis for
this control is likely multifaceted, certain major histo-
compatibility complex (MHC) class I alleles, such as
human leukocyte antigen (HLA)-B*27 and HLA-B*57,
are overrepresented among controllers [3], and genome-
wide association studies (GWASs) indicate that the MHC
is the dominant genetic correlate of chronic phase control
of viral replication [1]. Similarly, in macaque monkeys
infected with pathogenic SIV, control of viremia is
strongly influenced by MHC genotypes (reviewed in [4]).
However, not all infected individuals with protectiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the host parameters responsible for this incomplete pene-
trance is a major priority for HIV/AIDS research.
Despite the overall complexity of the host response to
HIV/SIV, there is consensus that CD8(+) T cells are pri-
mary mediators of sustained virus control [6,7]. Mul-
tiple studies have sought to identify key features of the
HIV-specific CD8(+) T cells underlying the variability
in chronic phase viral suppression. Compared with cells
from progressors, CD8(+) T cells isolated from control-
lers have been shown to preferentially target specific
viral proteins [8,9], express a greater number of cyto-
kines following in vitro peptide stimulation [10-12], ex-
hibit enhanced proliferative potential [10,13,14], and
rapidly upregulate and release cytotoxic granule pro-
teins upon encountering cognate MHC-peptide com-
plexes on the surface of infected cells [13,15,16].
Despite these functional correlates, compelling host pa-
rameters have not yet been identified to explain why
these immunological differences exist between control-
lers and progressors.
Within the past half-millennia, a small founder popu-
lation of cynomolgus macaques was deposited onto the
island of Mauritius [17] and expanded, in geographic
isolation, to constitute what is now a population of several
thousand animals. Due to founder effects, even highly
polymorphic loci, such as the MHC [18-20] and killer
immunoglobulin receptor (KIR) [21], are represented
by fewer than 10 extended haplotypes. This highly re-
stricted genetic diversity makes Mauritian cynomolgus
macaques (MCMs) an ideal animal model with which to
interrogate the role of genetic variation in complex clin-
ical phenotypes.
Sequencing large and complex eukaryotic genomes is
becoming increasingly accessible [22-25], and its in-
corporation into HIV infection and SIV challenge stud-
ies is now practical. Here, to begin to identify genetic
variation outside of the MHC that modifies control of
HIV/SIV in individuals possessing protection-associated
MHC alleles, we sequenced the whole genomes of 12
SIV-infected MCMs (six controllers and six progres-
sors) that shared the MHC M1 haplotype, which is the
most common of seven simple MHC haplotypes (M1 to
M7) in MCMs. The M1 haplotype was defined using
short tandem repeat-based typing across a 5 Mb region
of macaque chromosome 4 [20], and it encodes at least
three MHC class I alleles that altogether restrict eight
SIV-specific CD8(+) T-cell responses [26]. Recently, M1
was found to be enriched in, but not exclusive to, ma-
caques that control SIV [9]. Thus, the incomplete pene-
trance of M1-associated SIV control provides a tractable
non-human primate model with which to identify and
interrogate candidate minor determinants, or modifiers,
of MHC-associated AIDS virus control.Results
Whole genome sequencing of SIV-infected Mauritian
cynomolgus macaques
We retrospectively assembled a cohort (Cohort A) of
12 M1(+) male MCMs (Table 1), six M1/M1 animals and
six M1/M3 animals that were infected with SIVmac239 as
part of a previous study [9]. All animals used in this study
were SIV-naïve prior to experimental challenge, and did
not receive any antiviral intervention during the post-
challenge period of observation. For all downstream ana-
lyses, control in Cohort A animals was defined as suppres-
sion of peripheral viremia (viral load) to below 1,000 viral
RNA copies per milliliter of blood plasma (or 3Log10).
Although SIV viremia began to diverge within 12 weeks
following challenge (Figure 1), Cohort A viral loads did
not sufficiently stabilize to clearly differentiate durable
controllers (Group 1) from progressors (Group 2) until
approximately 52 weeks post-challenge.
In order to better understand the incomplete penetrance
of M1-associated control, we used the Illumina HiSeq
platform and 90 bp paired-end reads to sequence the ge-
nomes of all 12 Cohort A animals, as well as six additional
animals described in [9]. On average, 1.2 billion reads for
each animal were mapped to the rheMac2 rhesus ma-
caque (Macaca mulatta) reference genome (NCBI assem-
bly Mmul_051212). After mapping, these genomes had an
average of 35-fold coverage with 8.5% of the genome hav-
ing no coverage, which may have been a consequence of
mapping cynomolgus macaque (Macaca fascicularis) se-
quences to the rhesus macaque reference genome, large
gaps within the reference genome, difficulty in sequencing
GC-rich regions, or difficulties inherent to mapping com-
plex repeat regions. Individual animal mapping coverage
is shown in Table 1, and per chromosome coverage for
each animal in Cohort A is shown in Additional file 1.
Homozygous variants common to all animals were con-
sidered to be differences between the MCM population
overall and rheMac2 reference, and were excluded from
our analysis. Only polymorphic sites meeting a quality
threshold of at least 30 (Q ≥30) and covered by at least 10
reads in all 18 samples were included in the downstream
analyses (a total of 22,526,976 bp).
Assessing MHC identity in M1(+) macaques
We first asked whether whole genome sequencing could
be used to distinguish MHC-haplotype-identical animals
from one another by polymorphisms occurring within
the MHC on macaque chromosome 4. To test this, we
plotted the density of heterozygous variation across the
MHC using 10 kb bins (Figure 2). Consistent with results
from short tandem repeat-based MHC typing, within the
six M1/M3 animals we found widespread heterozygous
variation relative to the six M1/M1 and six M3/M3 homo-
zygous animals. As shown in Figure 2, minor peaks of
Table 1 Animals used for whole genome sequencing
Designation ID MHC GZMB 52 week viral load (log10) Sex Number of reads mapped Reference
Cohort A Group 1 cy0321 M1/M1 G1/G5 1.7 M 1222977688 [9]
cy0322 M1/M1 G1/G4 1.9 M 1093240092 [9]
cy0323 M1/M1 G1/G3 2.0 M 1161761415 [9]
cy0326 M1/M3 G1/G4 2.5 M 1014048607 [9]
cy0327 M1/M3 G1/G5 2.0 M 1158978497 [9]
cy0330 M1/M3 G3/G6 2.9 M 1120820126 [9]
Group 2 cy0320 M1/M1 G4/G4 5.9 M 1210339744 [9]
cy0324 M1/M1 G4/G4 5.7 M 1192434815 [9]
cy0325 M1/M1 G2/G3 6.8 M 1091870521 [9]
cy0328 M1/M3 G4/G4 6.3 M 1356197360 [9]
cy0329 M1/M3 G2/G3 6.7 M 1169431587 [9]
cy0331 M1/M3 G4/G5 5.5 M 1314518723 [9]
Outgroup cy0332 M3/M3 G2/G4 6.1 M 1206633787 [9]
cy0333 M3/M3 G3/G5 6.5 M 1217425129 [9]
cy0334 M3/M3 G2/G5 5.0 M 1094844832 [9]
cy0335 M3/M3 G1/G4 5.0 M 1298840412 [9]
cy0336 M3/M3 G2/G5 6.2 M 1244446132 [9]
cy0337 M3/M3 G3/G4 6.0 M 1357235243 [9]
Whole genome sequencing was performed on 18 SIV-infected Mauritian cynomolgus macaques. For each animal, the MHC genotype, GZMB genotype, 52 week
viral load (log10 viral RNA copies per milliliter of plasma), sex, and number of sequencing reads mapped to rheMac2 are shown for the 12 Cohort A M1(+) animals,
and an outgroup of 6 M3/M3 macaques.
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gotes, which corresponded to highly polymorphic loci,
such as the multicopy class I genes Mafa-A, Mafa-E,
and Mafa-B, which have undergone complex duplica-
tions and are poorly resolved in rheMac2.
Identifying regions of group-segregating variation
Our small cohort study is not powered to resolve
nucleotide-level variation associated with SIV control.
However, by leveraging the restricted genetic diversity




























Figure 1 Longitudinal viral loads for Cohort A. Longitudinal viral load p
indicate Group 1 animals (controllers) and open symbols indicate Group 2associated variation could be used to define candidate
control-modifying loci (CMLs) as genomic regions marked
by a high-density of individual control-segregating variants.
To establish our method, we hypothesized that M1(+) ho-
mozygotes could be distinguished from M1(+) heterozy-
gotes by high-density variation within the MHC. To test
this, we identified 14,787 variants across the genome that
strictly differed between the six M1/M1 and the M1/M3
animals and used 50 kb bins to plot variant density across
the genome (Figure 3A). As expected, we found that the













lot for 12 M1(+) Mauritian cynomolgus macaques. Shaded symbols
animals (progressors).
































































































































































Figure 2 Density of heterozygous variation across the MHC. Plots of heterozygous variant density (using 10 kb bins) across the MHC on
macaque chromosome 4. As expected, the density of variants is higher, and more widespread, in the M1/M3 heterozygotes compared with both
the M1 and M3 homozygotes. As shown in the upper leftmost plot, the occasional peaks of variation detected in the M1 and M3 homozygotes
correspond to polymorphic loci upon which reads for multiple alleles mapped.
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region of high variant density on chromosome 10, outside
of the MHC, which we were unable to reconcile. To re-
duce the rate of false discovery, and to narrow our
downstream analyses, we restricted subsequent analyses
to candidate regions (‘islands’ of co-segregating vari-
ants) marked by the highest 5% of genome-wide variant
densities.
Identifying candidate control-modifying loci
We next applied our haplotype-level analysis to Group 1
and Group 2 animals in order to identify genetic vari-
ation that modified MHC-associated control. Across the
genome, we identified 1,819 variant sites that strictly dif-
fered between Group 1 and Group 2, and plotted their
density across the genome (Figure 3B). As stated above,
to reduce the rate of false discovery in downstream ana-
lyses, we defined candidate CML as being marked by the
95th percentile of variant densities. We identified seven
candidate CMLs across chromosomes 2, 3, 7, 8, 9, 10,
and 14 (Figure 4). To determine the potential role of
these seven loci in modifying MHC-associated control,
we overlaid these variant-dense regions with Ensembl
gene annotations [27] (Table 2), and manually queried
the ImmPort database [28] to identify genes with known
immunological function. Interestingly, the candidate CML
on chromosome 7, which was marked by the highestdensity of control-segregating variants across the genome,
was the only candidate that contained immune-related
genes involved in T-cell function (Table 2). One of these
genes, granzyme B (gzmb), codes for a key component
of the cytotoxic granule machinery required for CD8-
mediated lysis of target cells. Additionally, high-level ex-
pression and rapid degranulation of cytotoxic granule
proteins, such as granzyme B, by epitope-specific CD8
(+) T cells is associated with the maintenance of control
during chronic HIV and SIV infection [13,16].
Variation in granzyme B and M1-associated control of SIV
In order to determine whether variation in gzmb modifies
SIV control, we began by defining alleles for the gene on
the basis of one or more nucleotide differences in the 5′
and 3′ untranslated regions (UTRs), exons, and introns.
Using this criterion, we identified a total of six gzmb alleles
within MCM (Figure S2A in Additional file 2). Five ani-
mals in Group 1 shared the Mafa-GzmB-01:01:01 allele
(designated 'G1'), which was entirely absent from Group 2
animals (Figure S2B in Additional file 2). Additionally, we
found that upon inclusion of additional M1(+) animals,
the association between G1 and control of SIV replication
remained intact (Figure S2C in Additional file 2). In
addition to intronic and synonymous differences, G1
differs from the other alleles by a conservative non-
synonymous polymorphism (lysine-to-arginine) that is






















































Position (Mb) on Macaque Chromosome 4
Macaque Chromosome
Figure 3 Variation differentiating MHC homozygotes from heterozygotes and SIV controllers from progressors. (A) Variants common to
six M1/M1 animals, but absent from six M1/M3 animals (and the reciprocal), were identified. Using a Manhattan plot, genome-wide variation was
plotted as variants per kilobase across 50 kb bins. Blue and red correspond to alternating chromosome numbers. The highest density of variation
across the genome marked the MHC on macaque chromosome 4. Although their annotations do not adequately depict the dispersion of these
multicopy loci throughout the MHC, Mamu-A, Mamu-B and Mamu-DQA are shown for reference. (B) Variants that strictly segregated between
Group 1 (controllers) and Group 2 (progressors) were identified, and the density of this variation was plotted across 21 macaque chromosomes
using 50 kb bins.
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associated with SIV control. Although this substitution
is located near a cluster of positively charged amino
acids within GZMB implicated in cytotoxicity [30], it
was not private to controllers (that is, it was also found
in some SIV progressors) and is thus unlikely to under-
lie differential MHC-associated SIV control.
In the absence of compelling coding variation that might
alter GZMB activity, we asked whether inheritance of G1
correlated with a difference in GZMB expression between
Group 1 and Group 2 animals. We used flow cytometry to
measure GZMB expression levels (median fluorescence in-
tensity) in peripheral CD8(+) cells at pre-infection and
acute infection time-points. We found higher GZMB ex-
pression by natural killer (NK) cells (CD8(+)CD3(-)), but
not by T cells (CD8(+)CD3(+)), in G1(+) macaques priorto infection (P = 0.0163) and at the peak of virus replica-
tion on day 14 post-challenge (P = 0.0167) (Figure S2D in
Additional file 2).
Given our retrospective observations, we sought to pro-
spectively test whether M1(+)G1(+) macaques control
chronic SIV replication at a higher frequency than M1(+)
G1(-) macaques. To test this hypothesis, we assembled an
MHC-identical cohort (Cohort B) of eight M1/M3 female
macaques (Table 3), composed of four G1(+) animals and
four G1(-) animals. All eight animals became infected fol-
lowing a single intrarectal challenge with 7,000 TCID50 of
SIVmac239. Viral loads for Cohort B animals began to di-
verge between 8 and 12 weeks post-challenge (Figure 5A).
Throughout the first 20 weeks of infection, one out of four
G1(+) animals, compared with three out of four G1(-) ani-
mals, demonstrated measurable post-peak control of SIV.
Chromosome 2
































































































Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Identification of candidate SIV control-modifying loci.Whole genome sequencing identified seven regions marked by control-segregating
variant densities meeting a 95th percentile cutoff (the highest 5% of genome-wide variant density) on macaque chromosomes 2, 3, 7, 8, 9, 10,
and 14. Plots depict variant densities (shown in black) across each of the candidate regions with Ensembl gene annotations overlaid (shown in
blue). The x-axes show distance (in megabases) relative to the center of each of the control-segregating regions.
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to demonstrate an increased frequency of SIV control, the
study was terminated at 32 weeks post-challenge. At
32 weeks post-challenge, two animals, one G1(+) and
one G1(-), exhibited durable maintenance of viral suppres-
sion. Altogether, we found no statistically significant dif-
ference in 32-week post-challenge viral loads between the
G1(+) and G1(-) groups (P = 0.7101).
Additionally, we used flow cytometry to measure ex vivo
GZMB expression levels within peripheral CD8(+) cells at
multiple acute infection time-points (Figure 5B). In con-
trast to our retrospective observations, we found no statis-
tically significant difference in GZMB expression levels
within NK cells (CD8(+)CD3(-)) or T cells (CD8(+)CD3
(+)) between G1(+) and G1(-) animals. Thus, despite
our retrospective observations, we were unable to pro-
spectively confirm an association between inheritanceTable 2 Genes within candidate control-modifying loci























Among the seven candidate loci identified through whole genome sequencing ana
annotations). Across these six regions, a total of 22 genes were identified, 9 of whic
chromosome, coordinates, gene length, and number of control-segregating variants oof G1 and higher expression of GZMB during acute SIV
infection.
Comparison to human genome-wide association studies
In order for animal models of AIDS virus control to
contribute to the understanding of human control of
HIV, the host processes underlying control need to be
shared. Despite the MHC being the major determinant
of control in both humans and macaques, it is not yet
clear whether minor determinants, or modifiers of the
major determinant, of control exist, and if they are con-
served. We sought to determine whether genomic vari-
ants associated with either control or acquisition of HIV
corresponded to the candidate CML that we identified
through our macaque analysis. We determined the hu-
man coordinates that corresponded to the candidate























lysis, six candidates contained coding genes (as determined using Ensembl
h contained control-segregating variants. For these 22 genes, the corresponding
ccurring within the gene are shown.
Table 3 Demographics of animals used in prospective
challenge study
ID MHC GZMB 32 week viral load (log10) Sex
cy0642 M1/M3 G1/G2 5.7 F
cy0643 M1/M3 G1/G2 5.8 F
cy0646 M1/M3 G2/G5 3.1 F
cy0648 M1/M3 G1/G4 2.3 F
cy0649 M1/M3 G1/G2 5.5 F
cy0651 M1/M3 G2/G3 4.9 F
cy0652 M1/M3 G4/G4 3.9 F
cy0654 M1/M3 G2/G5 5.7 F
Eight MHC-identical (M1/M3) Mauritian cynomolgus macaques were assembled
into a cohort to prospectively test the influence of granzyme B genetics on
MHC-associated control of SIV replication. Animal identifier, MHC genotype,
32 week viral loads (log10 viral RNA copies per milliliter of plasma), and sex are
shown for each animal. The granzyme B genotype for each animal is shown.



























































Figure 5 Longitudinal viral loads and granzyme B expression for Cohort
viral loads are plotted for all eight animals. Data-points corresponding to G1(+)
by open symbols. (B) Intracellular staining for granzyme B was performed to
fluorescence intensity is shown for both CD3(+)CD8(+) T cells (left panel) and
shaded symbols and G1(-) animals are indicated by open symbols.
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[1] and the International HIV Acquisition Consortium
(IHAC) [31], we did not identify any variants that met the
rigorous threshold for genome-wide statistical significance.Discussion
Although there have been recent hints at success [32-34],
the majority of attempts to immunize against HIV have
failed to demonstrate protective efficacy. However, rare
spontaneous chronic phase control of demonstrably
pathogenic AIDS virus replication provides evidence
that the host immune response is able to control HIV
and SIV replication. The strongest immunological cor-
relate of this control is host inheritance of at least one
of a handful of specific MHC class I alleles. However,
MHC-associated suppression of viral replication is in-






















B. The animals were followed for 32 weeks post-challenge. (A) Longitudinal
animals are indicated by shaded symbols, and G1(-) animals are indicated
quantify expression levels of granzyme B over time. Longitudinal median
CD3(-)CD8(+) NK cells (right panel). G1(+) animals are indicated by
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fies the MHC's protective effect.
Identifying modifiers of MHC-associated HIV control
in humans is confounded by multiple factors. First, the
heterogeneity of circulating HIV means that no two indi-
viduals are infected with the same virus, with the same
sequence or predilection to cause disease. Second, since
the symptoms of acute HIV infection are unremarkable,
few such cases present clinically. Lastly, an individual’s
ability to maintain control of HIV is likely influenced by
the durability of immune containment, which is mediated
by processes that begin to act during early infection. Since
poor containment during early chronic infection precedes
the loss of control of viral replication, proper assessment
of genetic effects on durable virus control necessitates
studying infection longitudinally, which is not practical in
humans.
Asian-origin macaques, such as rhesus and cynomolgus
macaques, are susceptible to SIV, and exhibit incompletely
penetrant MHC-associated control of virus replication.
Having been deposited on the island of Mauritius within
the past half-millennia, MCMs represent an exceptional
outbred population of Asian-origin macaques that experi-
enced a strong genetic bottleneck or founder effect. Their
restricted genetics makes them ideal for testing the broad
hypothesis that genetic variation outside of the MHC
modifies MHC-associated control of AIDS virus replica-
tion. Moreover, the haplotype sharing we demonstrate
here for SIV control is extensible to identifying genetic
correlates of other variable host responses to infectious
disease, pharmaceuticals, and transplantation.
Correlating minor genetic determinants of AIDS virus
control with immunologic effector mechanisms may eluci-
date measurable correlates of protection that can be used
to assess the efficacy of therapeutic and prophylactic HIV
vaccine candidates. Since the selection of interferon-
gamma [35] as the primary readout of T cell functionality
in vaccine studies is not based on any specific, functional
role in effective T-cell responses in individuals who spon-
taneously control HIV or SIV, incorporating measures of
other immune effector molecules, whose genetics underlie
differences in viral containment, might well inform studies
of vaccine efficacy.
While we believe our results serve as the most com-
prehensive interrogation of genetic variation segregating
AIDS virus controllers from progressors, they are subject
to the limitations inherent to mapping to highly complex
reference genomes, and are highly dependent on the com-
pleteness and accuracy of reference annotations. The rhe-
Mac2 draft of the rhesus macaque reference genome was
completed in 2006 and consequently did not benefit from
recent advances in genome sequencing and annotation
[36]. Refined rhesus macaque and cynomolgus macaque
genome sequences, with empiric gene annotations informedby transcript sequencing, are currently in development.
We anticipate that re-analysis of this dataset against
newer genomes may be informative, particularly given
the genetic dissimilarities between cynomolgus and rhe-
sus macaques [37,38], such as in complex regions or in
regions that are otherwise poorly resolved in the rhe-
Mac2 assembly. Segmental duplications or copy number
variation is notoriously difficult to assemble during ini-
tial genome assembly, and such complex regions may
harbor genes that influence viral control. For example,
our analysis was unable to identify and resolve differences
in genome structure (for example, large insertions, inver-
sions, and translocations) that exist between Mauritian-
origin cynomolgus macaques and Indian-origin rhesus
macaques. Additionally, although Cohort A was composed
of all male animals, we were unable to assess variation on
the Y chromosome due the rheMac2 reference genome
being based on a female rhesus macaque.
Our approach identified regions marked by high-density
control-segregating variation, which we designated candi-
date control-modifying loci. Surprisingly, across the seven
candidates that we identified, only one of these regions
comprised genes with known immunological function.
This region, found on chromosome 7, was marked by the
highest density of control-segregating variation and con-
tained genes implicated in cellular immunity such as those
encoding cathepsin G, granzyme B, granzyme H, and chy-
mase A. Previous studies have demonstrated differences
in virus-specific CD8(+) T-cell cytotoxicity between pro-
gressors and controllers [13,15,16], which made genetic
variation within or surrounding genes encoding cytotoxic
granule proteins compelling candidate modifiers of SIV
control. Granzyme B is one of the hallmark cytotoxic
granules required for cognate lysis of virus-infected cells
by CD8(+) effector cells, which strongly suggested that
our genome-wide analysis complemented the functional
correlations identified by other groups. We were able
to identify an allele of granzyme B, designated G1, that
correlated with SIV control in both the whole genome
sequencing cohort and a combined cohort that in-
cluded additional SIV-infected MCMs (Figure S2C in
Additional file 2). Additionally, we found that G1(+)
animals expressed higher levels of GZMB in NK cells
during early infection. However, we were unable to con-
firm a role for granzyme B variation in MHC-associated
SIV control upon prospectively challenging a cohort of
MHC-identical gzmb-defined animals.
There are several possible explanations for our dis-
crepant results, but a few merit specific attention. First,
the association that we identified between chromosome
7 variation and viral control may have been spurious.
Given that any combination of six animals will share
some number of variants, our analysis cannot distinguish
spurious association results from variants that causally
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omic analyses of SIV control in MCMs and other non-
human primates will serve to confirm and narrow
down regions of the genome that contain authentic
control-modifying variation. Second, it is conceivable
that we simply selected the wrong control-modifying
loci to test prospectively. We selected the candidate
CML on chromosome 7 based upon it having the high-
est density of control-segregating variation across the
genome and it being the only candidate to comprise
genes with established immune-related function. It is
important to note that we did not implement formal
statistical testing or power calculations in this exploratory
assessment of host genetic variation in SIV control, but as
genomic data for additional animals become available,
candidate gene discovery will benefit from such validation.
Lastly, although we attempted to control for as many
potentially confounding variables as possible when design-
ing our prospective challenge study (for example, virus
stock, dose, and route of challenge), a major variable that
was not held consistent between the retrospective cohort
(all male macaques) and the prospective cohort (all female
macaques) was the sex of the animals. In our experience,
female Indian-origin rhesus and Mauritian-origin cyno-
molgus macaques experience higher levels of SIVmac239
replication than their MHC-matched male contemporar-
ies. This anecdotal difference is complementary to a body
of literature on sex-specific differences in immunological
function (reviewed in [39-43]). It is desirable to assume
that an efficacious HIV vaccine will exploit an immuno-
logical process to universally confer protective immunity.
However, the combined results from our retrospective
and prospective studies anecdotally suggest that sex dif-
ferences may modulate AIDS virus control and, as a re-
cent National Institutes of Health policy change has
mandated [44], must be considered when designing and
evaluating genomic studies.
Conclusion
We provide the first whole genome sequencing study on
host control of AIDS virus replication. We confirmed
that whole genome sequencing could be used to identify
phenotype-associated genetic variation by assessing dif-
ferences between two groups of MHC-defined animals,
one group of six MHC homozygotes and one group of
six MHC heterozygotes. We further found that binning
variants into 50 kb bins and plotting variant density
across the genome accurately identified genomic regions
containing genetic variation that differentiated these a
priori MHC-defined animals. We then applied this ap-
proach to evaluate SIV controllers and progressors that
shared a protective MHC haplotype [9]. Through this
analysis, we identified seven regions across the macaque
genome that encompassed high-density control-segregatingvariation. We conclude that whole genome sequencing
can be used to identify genetic variation that distinguishes
groups of phenotypically different individuals. Using the
MCM model, such differences can be tested prospectively
for causality.
Materials and methods
Animals, viral infections, and viral loads
As part of a previous animal study [9,45], 18 male MCMs,
including the 12 Cohort A animals, were infected follow-
ing a single intrarectal challenge with 7,000 TCID50 of the
molecularly cloned SIVmac239 virus [GenBank: M33262].
Similarly, 8 female MCMs that comprised Cohort B were
infected following a single intrarectal challenge with 7,000
TCID50 of SIVmac239. For all 26 animals, SIV viral loads
were quantified using a previously described viral load
assay [46]. All animals used in this study were cared for
by the staff at the Wisconsin National Primate Research
Center according to regulations and guidelines of the
University of Wisconsin Institutional Animal Care and
Use Committee. Details of this study (UW-Madison
Animal Care and Use Protocol No. G00517) were approved
by the University of Wisconsin Institutional Animal Care
and Use Committee, in accordance with recommendations
of the Weatherall report.
DNA library preparation
Blood was drawn from 18 MCMs, and peripheral blood
mononuclear cells (PBMCs) were prepared, and genomic
DNA was isolated. Genomic DNA was then quantified
and quality checked using PicoGreen and gel analyses,
and subsequently used to construct Illumina paired-end
libraries according to the manufacturer’s protocol (Illu-
mina part number 1005361, revision D) with the modifi-
cations described below. A more complete description
is available at [47]. Libraries were prepared using Beckman
robotic workstations (Biomek FX and FXp models;
Beckman Coulter Inc., Brea, CA, USA). Briefly, 1 μg of
genomic DNA was sheared into fragments of approxi-
mately 300 to 400 bp with the Covaris E210 system
(Covaris Inc., Woburn, MA, USA). The sheared DNA
was then end-repaired, A-tailed and ligated to Illumina
multiplexing paired-end adaptors. Ligation-mediated
PCR was performed for six to eight cycles of amplification
using the 2X SOLiD Library High Fidelity Amplification
Mix (a custom product manufactured by Invitrogen
(Carlsbad, CA, USA)). Universal primer IMUX-P1.0 and a
pre-capture barcoded primer were used in the PCR
amplification. In total, 18 such barcodes were used on
these samples. Purification was performed with Agencourt
AMPure XP beads (Beckman Coulter Inc., Brea, CA,
USA) after enzymatic reactions, and following the final
purification, quantification and size distribution of the
ligation-mediated PCR product was determined using
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Genome sequencing
Library templates were prepared for sequencing using
Illumina’s cBot cluster generation system with TruSeq
PE Cluster Generation Kits (Illumina catalog number
PE-401-3001) according to the manufacturer’s protocol.
Briefly, these libraries were denatured with sodium hy-
droxide and diluted to 6 to 9 pM in hybridization buffer
in order to achieve a load density of approximately
800 K clusters/mm2. Each library was loaded in three
lanes of a HiSeq flow cell, and each lane was spiked with
2% phiX control library for run quality control. The
sample libraries then underwent bridge amplification to
form clonal clusters, followed by hybridization with the
sequencing primer. Sequencing runs were performed in
paired-end mode using the Illumina HiSeq 2000 platform.
Using the TruSeq SBS Kits (Illumina catalog number
FC-401-3001), sequencing-by-synthesis reactions were
extended for 101 cycles from each end, with an add-
itional seven cycles for the index read. Sequencing runs
generated approximately 350 to 500 million filter-pass
reads on each flowcell lane, yielding an average of 44 Gb
per lane. On average, 118 Gb of unique aligned sequence
was generated per sample.
Illumina analysis and variant calls
Initial analysis of Illumina sequence reads was performed
using the Baylor College of Medicine (BCM)-HGSC Mer-
cury analysis pipeline [48]. This pipeline addresses all as-
pects of data processing, moving data stepwise through
various analysis tools from the initial sequence generation
on the instrument to the generation of alignments (BAM
files). There are four main steps in this pipeline. First Illu-
mina’s software is used to perform base calling and filter
out low quality reads. These reads were then aligned to
rheMac2 using the Burrows-Wheeler aligner (BWA) [49],
and Picard tools was used to mark PCR duplicates and to
aggregate alignments and generate a single BAM file for
each animal. These alignments were deposited into the
NCBI Sequence Read Archive (SRA), and are accessible
through BioProject [BioProject: PRJNA257343], or SRA
[SRA: SRP045278].
SAMtools v0.1.17 [50] was used to call variants, in-
cluding substitutions and small indels, and to produce a
variant call file (VCF). The caller only used reads with
mapping quality greater than 10, and did not apply add-
itional filters in order to maximize sensitivity. Next, an-
notation data were added to the VCF using SnpEff v3.3
[51]. Per-sample read depths (RDPs) were computed
using custom scripts. Next, snpSift v3.6 [52] was used to
filter on variants supported by at least 10 reads for all
18 animals (RDP >9), and that met a quality thresholdof at least 30 (Q ≥30). To generate a population-level
VCF for use in downstream analyses, snpSift v3.6 [52]
was used to exclude variants corresponding to species-
specific differences between the MCM and the rheMac2
reference sequence, which were identified as homozy-
gous variants present in all animals.
Genome-wide coverage analysis and mapping statistics
To generate coverage plots, BEDTools genomecov [27]
was used to extract the read depth of all genomic posi-
tions from each sample’s BAM file. Next, arithmetic
mean read depths were calculated across the genome
using 10 kb bins, and plots were generated using a cus-
tom tool (source code available at [28]). Additionally,
the total number of reads mapping to rheMac2 were
calculated by running SAMtools flagstat [50] on each
sample’s BAM file.
Evaluation of heterozygous variation within the MHC of
short tandem repeat-typed MHC homozygotes and
heterozygotes
Using the population-level VCF, snpSift v3.6 [52] was
used to generate animal-specific chromosome 4 VCFs
for 18 of the animals, including six M1 homozygotes, six
M1/M3 animals, and six M3 homozygotes. Next, each
animal-specific VCF was filtered using snpSift v3.6 [52]
to remove homozygous variants prior to being loaded
into the VCFtools [53] SNPdensity tool in order to cal-
culate the density of heterozygous variants, using 10 kb
bins, across macaque chromosome 4. Prism v5.0
(GraphPad, La Jolla, CA) was used to plot heterozy-
gous variant density spanning the MHC for each ani-
mal (Figure 2).
Calculation of group-segregating variant densities and
generation of gene overlay plots
To identify variants that differentiated the six M1/M1
animals from the six M1/M3 animals, the population-
level VCF was filtered using snpSift v3.6 [52] to preserve
sites that matched the reference in all six M1/M1 ani-
mals and variant in all six M1/M3 animals (and the re-
ciprocal). Once generated, this M1/M1 versus M1/M3
VCF was manually sorted and curated to exclude vari-
ants that corresponded to non-canonical chromosomes
in the rheMac2 genome (for example, chr4_random).
Identical methodology was used to identify sites that
strictly differed between all Group 1 animals (control-
lers) and all six Group 2 animals (progressors). In
order to calculate and plot group-segregating variant
densities (corresponding to both substitutions and
short indels), these group-specific VCFs were fed into
the VCFtools SNPdensity program [53]. Genome-wide
variant density was calculated using 50 kb bins to as-
sess differences between M1/M1 and M1/M3 animals
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(Figures 3B and 4). Downstream analyses were focused
on regions of the macaque genome marked by the 95th
percentile of genome-wide variant density (or the highest
5% of variant density across the genome). Gene annotations
were downloaded from the rhesus macaque (Mmul_1) as-
sembly in release 75 of Ensembl [54] in order to generate
the gene overlays for the variant density plots correspond-
ing to the seven candidate control-modifying loci (Figure 4).
Genes contained within candidate CMLs were determined
to have immune-related function by manually querying the
ImmPort database [29]. Gene overlay plots were created
using GraphPad Prism v5.0.Comparison to human GWASs
In order to determine whether human genomic regions
corresponding to the candidate macaque CMLs were
implicated in HIV disease, we interrogated the Ricopili
database [55]. This disease-focused database aggregates
results from various GWAS, in this case, the Inter-
national HIV controller study [1] and the International
HIV Acquisition Consortium (IHAC) [31]. We obtained
the P-values for single-nucleotide polymorphisms within
the corresponding regions, and found that none of them
reached the GWAS statistical threshold for significance
(P <5E-8).Granzyme B typing by sequencing
Briefly, genomic DNA was isolated and used as template
for gzmb amplification. For PCR, the forward primer
(5′-GGGCAGCATTCACAGAAA-3′) and the reverse
primer (5′-CCTGCATAGCACAGAACTGG-3′) were
used to amplify a 3.4 kb amplicon corresponding to the
region of the rhesus macaque genome (chr7:87,509,903-
87,513,329) containing the gzmb gene. Amplification was
performed using Phusion HF Master Mix (Thermo Scientific,
Waltham, MA, USA), in a total reaction volume of 25 μl.
Reactions were cycled as follows: 98°C for 2 minutes
followed by 35 cycles of 98°C for 10 s, 62°C for 15 s, 72°C
for 3 minutes. A final extension was performed at 72°C
for 10 minutes, and the reaction was held at 10°C until be-
ing run on an agarose gel. Bands corresponding to the
3.4 kb product were extracted and Illumina compatible li-
braries were generated using the Illumina Nextera XT kit
(catalog number FC-131-1024). Sequencing libraries were
cleaned using the Agencourt Ampure XP system (catalog
number A63882) and subsequently sequenced on the Illu-
mina MiSeq. On average, 74,000 reads per sample were
generated. Low quality (Q <30) and short reads (<100 bp)
were removed and the remaining reads were mapped
against the rhesus macaque gzmb reference sequence.
Variants in gzmb were phased using Beagle v4.0 [56],
and six alleles were defined.Evaluating granzyme B expression
For Cohort A, cryopreserved PBMCs were thawed at 37°C
and washed once in R10 media prior to staining. As sam-
ples permitted, 1 to 2 million PBMCs were stained with
2 μl anti-CD3 Alexa Fluor 700 (clone SP34-2; BD Biosci-
ences, San Jose, CA, USA) and 1 μl anti-CD8 Pacific Blue
(clone RPA-T8; BD Biosciences) in 150 μl R10 for 30 mi-
nutes at room temperature. Cells were then washed with
fluorescence-activated cell sorting (FACS) buffer, and fixed
with 1% paraformaldehyde. Cells were fixed for 30 minutes
at 4°C, and washed once with FACS buffer. Cells were
permeabilized by adding 75 μl medium B (Life Technolo-
gies, Grand Island, NY, USA), and simultaneously stained
for granzyme B with 1 μl anti-GZMB allophycocyanin
(clone GB12; Life Technologies) for 30 minutes at room
temperature. Cells were washed twice with FACS buffer,
fixed in 1% paraformaldehyde, and placed at 4°C until be-
ing run on a BD-LSRII (BD Biosciences). Analysis was
performed using FlowJo software (version 9.7.1, Tree Star,
Ashland, OR, USA). This methodology was then used to
assess GZMB expression in Cohort B, with the exception
of staining freshly processed cells, and not cryopreserved
cells.
Data accessibility
Whole genome alignments to rheMac2 for all 18 retro-
spective cohort animals were deposited into the NCBI
SRA as BAM files, and are accessible through BioProject
[BioProject: PRJNA257343] or through SRA [SRA:
SRP045278]. The six granzyme B alleles identified in
this study have been deposited to GenBank and can be
accessed through their corresponding accession numbers,
as follows: Mafa-GzmB:01:01:01 [GenBank: KM281203],
Mafa-GzmB:01:01:02 [GenBank: KM281207], Mafa-
GzmB:02:01:01 [GenBank: KM281204],Mafa-GzmB:02:01:02
[GenBank: KM281205], Mafa-GzmB:02:01:03 [GenBank:
KM281206], and Mafa-GzmB:02:01:04 [GenBank: KM2
81208].
Additional files
Additional file 1: Figure S1. Whole genome sequencing coverage for
Cohort A. Mapping coverage for each Cohort A animal is shown across
21 macaque chromosomes. The y-axis corresponds to the number of
reads, and the x-axis corresponds to the position on the indicated
chromosome. Gaps reflect regions in which reads did not map to the
rhesus macaque (rheMac2) reference genome.
Additional file 2: Figure S2. Granzyme B in Cohort A. (A) Six distinct
alleles for gzmb were identified for MCMs. A single non-synonymous
coding polymorphism (black bar) that differentiates two of the alleles from
the other four. This conservative lysine-arginine mutation is accompanied
by various synonymous (green bar) and intronic (blue bar) polymorphisms.
At 52 weeks post-challenge, G1(+) animals had significantly lower viral loads
than G1(-) animals, both within (B) Cohort A (P =0.0001; unpaired t-test;
two-sided P-value), and (C) a cohort including 7 additional M1(+) animals
(P =0.0002; unpaired t-test; two-sided P-value). (D) Flow cytometry was used
to measure granzyme B expression within CD3(+)CD8(+) T cells (left panel)
Ericsen et al. Genome Biology 2014, 15:478 Page 13 of 14
http://genomebiology.com/2014/15/11/478and CD3(-)CD8(+) NK cells (right panel). Median fluorescence intensity (MFI)
for GZMB is displayed on the y-axis, and plotted for G1(+) animals (shaded
symbols) and G1(-) animals (open symbols) at 0, 2, 3, 6, 8, 10, and 12 weeks
post-challenge. Asterisks mark time-points at which the difference in
granzyme B expression between G1(+) and G1(-) samples was statistically
significant (P <0.05).
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